Academy’s Monthly Bulletin: March 2024

Academy's Monthly Bulletin: March 2024

A Monthly Newsletter Dedicated to Our Academy Membership Community!

Academy's Update for March 2024:

Here is the summary of our posted lectures, YouTube videos & updates for March 2024:

[YouTube Content]:
Medical Complications Associated with Anorexia Nervosa

Anorexia nervosa, characterized by extreme restriction of food intake and an intense fear of gaining weight, can lead to a multitude of serious health issues. Understanding medical complications associated with anorexia nervosa is crucial for healthcare professionals to provide effective and comprehensive care to individuals grappling with this severe eating disorder. 

This YouTube video will summarize the list of medical complications associated with Anorexia Nervosa.

[Facebook Live]: *New Feature*

* Facebook Live is a new feature for our academy students. We will be doing these live sessions on a monthly basis in our academy’s Facebook group.

Prepare for an informative Facebook Live session by Dr. Harvinder Singh, where he will discuss:

  • Recent clinically relevant articles published in the field of psychiatry.
  • Psychiatry Updates regarding psychopharmacology.
  • Academy’s updates 
  • and many more …

In our first Facebook Live session, following topics were discussed:

(1) MDD with Psychotic Features:

  • Pharmacological Treatments for Psychotic Depression.

(2) Geriatric Psychiatry:

  • The Use of Dispensary-Obtained Tetrahydrocannabinol as a Treatment for Neuropsychiatric Symptoms of Dementia.

(3) Major Depressive Disorder:

  • Association between Dietary Sugar Intake & Depression in US Adults.

(4) Adult ADHD:

  • Solriamfetol for Attention-Deficit/Hyperactivity Disorder in Adults.

(5) Schizophrenia:

  • Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia.

[YouTube Content]:
Role of Olanzapine for Bipolar Mania with Mixed Features.

Treatment for bipolar mixed episodes involves a comprehensive approach to address the complex interplay of manic and depressive symptoms simultaneously experienced by individuals with bipolar disorder.

This YouTube video will summarize the role of Olanzapine in the management of bipolar mixed episodes.

[Clinical Case Discussion]:
Antidepressants and Anticoagulants.

Dr. Satinderpal Kaur (Family Medicine) & Dr. Harvinder Singh (Psychiatry) will continue their discussion to integrate clinical cases from Psychiatry and Medicine.

This clinical case discussion #5 will focus on:

  1. How to choose an antidepressant in a patient on Warfarin. 
  2. Understanding antiplatelet agents and anticoagulants.
  3. Warfarin monitoring and drug interactions.

[YouTube Content]:
Cariprazine: How to Dose for MDD Augmentation?

Cariprazine, an atypical antipsychotic, has shown promise in the augmentation of treatment for Major Depressive Disorder (MDD). In cases where standard antidepressant therapies alone may not yield sufficient improvement, adding cariprazine to the treatment regimen may enhance efficacy.

This YouTube video will discuss the basics of how to dose Cariprazine for MDD augmentation.

[New Academy Content]:
Clozapine Withdrawal: Cholinergic Rebound

Clozapine, an atypical antipsychotic, is known for its efficacy in treating refractory schizophrenia, but its discontinuation requires careful consideration due to the risk of withdrawal symptoms, including cholinergic rebound.

Dr. Singh will discuss this clinically relevant topic in the academy’s new chapter addition this month.

[Psychiatry Education Forum Academy Updates]:
MM120 Receives FDA Breakthrough Therapy Designation for GAD

In a groundbreaking development within the mental health sphere, MM120, an innovative therapeutic compound, has been granted the prestigious Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of Generalized Anxiety Disorder (GAD). This landmark decision not only underscores the potential of MM120 in transforming GAD treatment paradigms but also shines a beacon of hope for millions grappling with this debilitating condition.



This is a closed membership for medical professionals only.

  • 400+ Clinically Relevant Chapters: Each chapter within these sections is of direct clinical relevance for your daily practice. 
  • Journal Club: we will post the most recently published psychiatry articles relevant to your daily clinical practice.
  • Clinical Case Discussion: Dr. Singh (Psychiatry) and Dr. Kaur (Family Medicine) discuss clinical cases to integrate the clinical cases from Psychiatry and Medicine.
  • Discussion Forum & Community: Connect with other medical professionals and discuss your difficult-to-treat clinical cases.
  • Goal: is to have all important clinically relevant topics in one place for ease of access.
$ 150/YR
$ 99/YR


Email us your student information (program information and way to confirm your student status) to:

© 2024 All Rights Reserved.

Join Email Newsletter

* indicates required

Related Articles